Stephen M Mitchell

7166714, Jan 23, 2007

Dec 31, 2003

10/750262

Daniel E. H. Afar - Brisbane CA, US
Rene S. Hubert - Los Angeles CA, US
Kahan Leong - Playa Del Rey CA, US
Arthur B. Raitano - Los Angeles CA, US
Douglas C. Saffran - Encinitas CA, US
Stephen C. Mitchell - Gurnee IL, US

Agensys, Inc. - Santa Monica CA

C07H 21/02
C07H 21/04
C12N 15/00

536 231, 4353201, 435 691

Described is a novel family of cell surface serpentine transmembrane antigens. Two of the proteins in this family are exclusively or predominantly expressed in the prostate, as well as in prostate cancer, and thus members of this family have been termed “STEAP” (Six Transmembrane Epithelial Antigens of the Prostate). Four particular human STEAPs are described and characterized herein. The human STEAPs exhibit a high degree of structural conservation among them but show no significant structural homology to any known human proteins. The prototype member of the STEAP family, STEAP-1, appears to be a type IIIa membrane protein expressed predominantly in prostate cells in normal human tissues. Structurally, STEAP-1 is a 339 amino acid protein characterized by a molecular topology of six transmembrane domains and intracellular N- and C-termini, suggesting that it folds in a “serpentine” manner into three extracellular and two intracellular loops. STEAP-1 protein expression is maintained at high levels across various stages of prostate cancer.

7803916, Sep 28, 2010

Sep 16, 2008

12/211702

Daniel E. Afar - Fremont CA, US
Rene S. Hubert - Los Angeles CA, US
Stephen Chappell Mitchell - Gurnee IL, US

Agensys Inc. - Santa Monica CA

C07K 16/00
C12N 5/12

5303871, 5303971, 5303973, 435326

A novel testis-specific gene expressed in human prostate cancer, designated 22P4F11, is described. Analysis of 22P4F11 mRNA expression in normal prostate, prostate tumor xenografts, and a variety of normal tissues indicates that the expression of this gene is testis specific in normal tissues. The 22P4F11 gene is also expressed in human prostate tumors, in some cases at high levels. A full length cDNA encoding 22P4F11 is provided. The 22P4F11 transcript and/or protein may represent a useful diagnostic marker and/or therapeutic target for prostate cancer.

7981624, Jul 19, 2011

Feb 19, 2009

12/389293

Daniel E. H. Afar - Fremont CA, US
Rene S. Hubert - Los Angeles CA, US
Kahan Leong - Playa Del Rey CA, US
Arthur B. Raitano - Los Angeles CA, US
Douglas Saffran - Encinitas CA, US
Stephen C. Mitchell - Gurnee IL, US
Aya Jakobovits - Beverly Hills CA, US
Mary Faris - Los Angeles CA, US
Igor Vivanco - Los Angeles CA, US

Agensys, Inc. - Santa Monica CA

G01N 33/53

435 71

Compositions for the diagnosis and therapy of prostate and colon cancer, derived from or based on a novel prostate-specific, androgen-regulated, cell membrane associated and secreted serine protease termed 20P1F12/TMPRSS2 are described. A full length cDNA comprising the entire coding sequence of the 20P1F12/TMPRSS2 gene (also designated 20P1F12-GTC1 herein) is provided (FIG. ). Among the compositions provided are antibodies that bind to 20P1F12/TMPRSS2 proteins and polypeptide fragments thereof, including antibodies labeled with a detectable marker or toxin or therapeutic composition. The invention also provides prognostic and diagnostic methods of examining a biological sample for evidence of disregulated cellular growth by comparing the status of 20P1F12/TMPRSS2 in the biological sample to the status of 20P1F12/TMPRSS2 in a corresponding normal sample, wherein alterations in the status of 20P1F12/TMPRSS2 in the biological sample are associated with disregulated cellular growth. The invention further provides various therapeutic compositions and strategies for treating prostate cancer, including particularly, 20P1F12/TMPRSS2 polypeptide and anti-20P1F12/TMPRSS2 antibody therapy methods and compositions, cancer vaccines, and small molecule therapy.

20050063975, Mar 24, 2005

Jan 5, 2004

10/752421

Daniel Afar - Brisbane CA, US
Rene Hubert - Los Angeles CA, US
Arthur Raitano - Los Angeles CA, US
Douglas Saffran - Encinitas CA, US
Stephen Mitchell - Gurnee IL, US

C12Q001/68
G01N033/574
C07H021/04
A61K039/395

424155100, 435069100, 435320100, 435325000, 530350000, 530388800, 435006000, 435007230, 536023500

Described is a novel family of cell surface serpentine transmembrane antigens. Two of the proteins in this family are exclusively or predominantly expressed in the prostate, as well as in prostate cancer, and thus members of this family have been termed “STEAP” (ix ransmembrane pithelial ntigen of the rostate). Four particular human STEAPs are described and characterized herein. The human STEAPs exhibit a high degree of structural conservation among them but show no significant structural homology to any known human proteins. The prototype member of the STEAP family, STEAP-1, appears to be a type IIImembrane protein expressed predominantly in prostate cells in normal human tissues. Structurally, STEAP-1 is a 339 amino acid protein characterized by a molecular topology of six transmembrane domains and intracellular N- and C-termini, suggesting that it folds in a “serpentine” manner into three extracellular and two intracellular loops. STEAP-1 protein expression is maintained at high levels across various stages of prostate cancer. Moreover, STEAP-1 is highly over-expressed in certain other human cancers.

20060275304, Dec 7, 2006

Aug 9, 2005

11/200973

Daniel Afar - Fremont CA, US
Rene Hubert - Los Angeles CA, US
Kahan Leong - Playa Del Rey CA, US
Arthur Raitano - Los Angeles CA, US
Douglas Saffran - Encinitas CA, US
Stephen Mitchell - Gurnee IL, US

AGENSYS, INC. - Santa Monica CA

A61K 39/395
C12Q 1/68
C07H 21/04
C12P 21/06
C07K 16/30
C07K 14/82
C07K 16/46

424155100, 435006000, 435069100, 435320100, 435325000, 530388800, 530350000, 424178100, 536023500

Compositions for the diagnosis and therapy of prostate and colon cancer, derived from or based on a novel prostate-specific, androgen-regulated, cell surface serine protease termed 20P1F12/TMPRSS2 are described. A full length cDNA comprising the entire coding sequence of the 20P1F12/TMPRSS2 gene (also designated 20P1F12-GTC1 herein) is provided (FIG. ). Among the compositions provides are antibodies that bind to 20P1F12/TMPRSS2 proteins and polypeptide fragments thereof, including antibodies labeled with a detectable marker or toxin or therapeutic composition. Several monoclonal antibodies specifically reactive with 20P1F12/TMPRSS2 are also described herein.